
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is well-positioned for continued success with promising products like DefenCath and Rezzayo in its portfolio. The recent acquisition of Melinta and the potential approval of Rezafungin could drive further revenue growth. The company's focus on expansion and optimization, along with a diverse workforce, add to its potential for long-term success.
Bears say
Cormedix is heavily reliant on one product, DefenCath, for its current revenue and future growth. While DefenCath's revenue for 2026 exceeded expectations, there are potential challenges in obtaining Medicare Advantage contracting and ongoing negotiations could impact the drug's ability to exceed guidance. The company's other key product, Rezzayo, has shown positive results in clinical trials, but its potential for FDA approval in a new indication remains uncertain. Overall, Cormedix faces significant risks and dependency on a few key products, leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares